Pharmaceuticals, Biotechnology and Life Sciences
Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE)…
Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study…
Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended…
Record Annual Total Revenue of $104.8M, Representing Eighth Consecutive Year of Revenue Growth Company Guides to 2022 Total Revenues of…
Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids…
Orphazyme A/SCompany announcementNo. 07/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US))…
ADELAIDE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) — Bionomics Limited (ASX: BNO, Nasdaq: BNOX), today announced its half-year report for…
Dante Labs meets with Abu Dhabi Executive Office Dante Labs CEO Andrea Riposati and Carlo Logli meet with Dr. Fatima…
CINCINNATI, Feb. 23, 2022 (GLOBE NEWSWIRE) — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a…
Affirms the advancements of innovative biosimulation technology and its growing impact in R&DPRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) —…